The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location

Authors

SKŘIČKOVÁ Jana BORTLÍČEK Zbyněk HEJDUK Karel PESEK Milos KOLEK Vitezslav KOUBKOVA Leona TOMÍŠKOVÁ Marcela ROUBEC Jaromír HAVEL Libor SALAJKA František

Year of publication 2014
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description This study evaluates treatment outcomes in 127 non-small cell lung cancer (NSCLC) patients from Czech Republic according to activated mutations located in exons 19 (Del 19) and 21 (L858R).

You are running an old browser version. We recommend updating your browser to its latest version.

More info